

CORRESPONDENCE OPEN



Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib

© The Author(s) 2023

Blood Cancer Journal (2023)13:65 ; <https://doi.org/10.1038/s41408-023-00834-6>

INTRODUCTION

The coronavirus disease 2019 (Covid19) pandemic caused by the spreading of the coronavirus SARS-CoV-2 has led to substantial mortality in patients with hematological diseases [1]. During the first wave of pandemic, patients with Philadelphia-negative chronic myeloproliferative neoplasms (MPN) including essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF) were reported at higher risk of acquiring SARS-CoV-2 and of having a poor outcome after infection, with a mortality rate of about 30%, increasing to 48% in MF patients [2].

Ruxolitinib is a *JAK1/2* inhibitor that is widely used both in MF and PV [3]. It may affect immunological response by decreasing the production of pro-inflammatory cytokines and by altering the function of several immune cells, including macrophages and B/T-lymphocytes [4]. Its use and discontinuation have been identified as risk factors for SARS-CoV-2 infection and Covid19-related death [5]. Additionally, ruxolitinib-treated patients show lower serological response to anti-SARS-CoV-2 vaccination [6, 7].

Previous studies on Covid19 in MPN patients have included patients regardless of treatment type, with few patients treated with ruxolitinib at the time of the pandemic. Here, we explored features associated with Covid19 disease and survival after Covid19 in a large cohort of ruxolitinib-treated PV and MF patients.

This analysis could provide useful information for identifying those ruxolitinib-treated patients that are at higher risk of SARS-CoV-2 infection and assessing prognostic factors for survival in a homogeneously treated cohort. The final objective is to provide decision-support tools for viral therapy and/or hospitalization.

METHODS

Study setting

The observational retrospective cohort studies “RUX-MF and “PV-ARC” were promoted by the IRCCS Azienda Ospedaliero-Universitaria S. Orsola-Malpighi, Bologna, Italy. The PV-ARC study involves 934 PV patients, while the “RUX-MF” study collects 886 MF patients in chronic phase who received ruxolitinib outside clinical trials. Details of protocol design, list of participating Centres and operational procedures have already been reported [8, 9]. For the purposes of this analysis, data concerning MF/PV and characteristics related to first Covid19 infections during ruxolitinib therapy were recorded. The data cut-off date was January 2022.

Waves of the Covid19 pandemic were divided into three periods, according to the type of predominant circulating variants in Europe: first (wild-type variant, February–June 2020); second (alpha/beta/gamma variants, July 2020–June 2021) and third (delta variant, July 2021–January 2022).

Covid19 severity was categorized according to the NIH Guidelines [10].

Statistical analysis

Statistical analysis was carried out at the biostatistics laboratory of the MPN Unit at the Institute of Hematology “L. and A. Seràgnoli”, IRCCS Azienda Ospedaliero-Universitaria, Bologna.

Continuous variables have been summarized by their median and range, and categorical variables by count and relative frequency (%) of each category. Comparisons of quantitative variables between groups were carried out by Wilcoxon–Mann–Whitney rank-sum test; association between categorical variables was tested by the χ^2 test. By Receiver Operating Characteristic (ROC) curve, the optimal cut-off for neutrophil to lymphocyte ratio (NLR) was found at 5.5 (AUC: 0.66) for hospitalization and at 6.8 (AUC: 0.71) for death.

Using Cox proportional hazard model, association with COVID-19 hospitalization and Covid19-related survival was evaluated for the following variables: age \geq 70 years, sex, presence of at least one comorbidity, MPN type, NLR \geq 5.5 (hospitalization), NLR \geq 6.8, vaccination, wave, previous thrombosis, and platelet count/hemoglobin at infection. The same factors were evaluated using a logistic regression model for PV and MF patients (adding DIPSS and spleen response at Covid19 infection in the latter). The association between thromboses that occurred during the pandemic and Covid19 infection, MPN type and NLR was also investigated.

For all analyses, the starting time was February 2020, corresponding to the pandemic start.

Overall survival was calculated by Kaplan–Meier analysis, starting from the date of Covid19 infection and considering only Covid19-related deaths.

Pearson’s test was used to measure the collinearity of covariates.

Akaike’s Information Criterion (AIC) and Schwarz’s Bayesian Information Criterion (BIC) were used to choose the model that best fits the data.

For all tested hypotheses, two-tailed *p*-values $<$ 0.05 were considered significant. Statistical analyses were performed using STATA Software, 15.1 (StataCorp LP, College Station TX, USA).

Received: 11 January 2023 Revised: 28 March 2023 Accepted: 11 April 2023

Published online: 03 May 2023

Table 1. Patients' characteristics by SARS-CoV-2 infection and hospitalization.

| Characteristics | Overall cohort (n. 560) | | | SARS-CoV-2 infected patients (n. 83) | | |
|--|-------------------------|------------------|------------------|--------------------------------------|----------------------|------------------|
| | Non-covid (n. 477) | Covid (n. 83) | p value | Non-hospitalized (n. 38) | Hospitalized (n. 45) | p value |
| Male sex, n (%) | 249 (52.2%) | 47 (56.6%) | 0.46 | 20 (52.7%) | 27 (60%) | 0.50 |
| Age at pandemic start, median (IQR) | 70.5 (32.9–89.5) | 70.5 (46.4–89.4) | 0.91 | 65.3 (46–79.7) | 72.7 (52.8–89.4) | 0.005 |
| ≥70 yrs | 153 (32.1%) | 29 (34.9%) | 0.61 | 9 (23.7%) | 20 (44.4%) | 0.05 |
| Comorbidities, no. (%) | 170 (35.61%) | 23 (27.7%) | 0.16 | 9 (23.7%) | 14 (31.11%) | 0.45 |
| MF diagnosis, no. (%) | 346 (72.5%) | 67 (80.7%) | 0.12 | 29 (76.3%) | 38 (84.4%) | 0.35 |
| Previous thrombosis, no. (% on evaluable) | 81 (20.7%) | 8 (13.3%) | 0.18 | 2 (8.70%) | 6 (16.22%) | 0.41 |
| Median time from MF/PV diagnosis to SARS-CoV-2 infection, years (range) | NA | 6 (0.4–28.4) | NA | 6.9 (0.7–28.4) | 5.6 (0.4–21.5) | 0.50 |
| Median RUX duration at SARS-CoV-2 infection, years (range) | NA | 2.8 (0.4–9.9) | NA | 3 (0.3–9.9) | 2.7 (0.4–8.1) | 0.85 |
| Ruxolitinib discontinuation during SARS-CoV-2 infection, no (%) | NA | 9 | NA | 0 | 9 (20%) | 0.004 |
| Ruxolitinib dose, no. (% on 544 evaluable) | | | 0.56 | | | 0.93 |
| 5–10 BID | 279 (59.9%) | 44 (56.4%) | | 19 (55.8%) | 25 (56.8%) | |
| 15–20 BID | 187 (40.1%) | 34 (43.6%) | | 15 (44.1%) | 19 (43.2%) | |
| Chemistry at SARS-CoV-2 infection, median (IQR) | | | | | | |
| Hemoglobin g/dL | NA | 10.55 (4.6–15.1) | | 10.8 (4.6–15.1) | 10 (6–13.8) | 0.11 |
| Hematocrit % | NA | 32.9 (11.7–47.2) | | 33.9 (11.7–47.2) | 31.8 (18.8–46.0) | 0.35 |
| WBC ×10 ⁹ /L | NA | 7.17 (1.0–115.1) | | 6.5 (2.6–28.6) | 9.0 (1.0–115.1) | 0.18 |
| Neutrophils | NA | 5.1 (0.8–99) | | 4.2 (1.7–18.6) | 7.2 (0.8–99) | 0.04 |
| Lymphocytes | NA | 1.12 (0.2–25.0) | | 1.10 (0.4–13.3) | 1.15 (0.2–25.0) | 0.72 |
| N/L ratio | NA | 4.4 (1.4–17.3) | | 3.5 (1.4–11.9) | 5.6 (2.0–17.3) | 0.04 |
| Platelets ×10 ⁹ /L | NA | 183 (2–707) | | 226 (38–707) | 150 (2–487) | 0.02 |
| SARS-CoV-2 vaccination before infection, no. (% on 467 evaluable) | 324 (83.5%) | 26 (32.9%) | <0.001 | 20 (55.6%) | 6 (13.9%) | <0.001 |
| SARS-CoV-2 vaccination dose before infection, no. (% on 346 evaluable) | | | 0.48 | | | 0.24 |
| 1 dose | 5/320 (1.6%) | 1/26 (3.9%) | | 0 (0%) | 1 (14.3%) | |
| 2 doses | 88 (27.5%) | 9 (34.6%) | | 7 (36.8%) | 2 (28.6%) | |
| 3 doses | 227 (70.9%) | 16 (61.5%) | | 12 (63.2%) | 4 (61.5%) | |

The characters in bold were entered for two different reasons: (1) For *p* values, only statistically significant *p* values have been marked in bold here. (2) For the characteristic names. All 'titles' of the different characteristics have been entered in bold.

RESULTS

Study cohort

Overall, 886 MF and 172 PV patients treated with ruxolitinib outside clinical trials have been registered in the RUX-MF and in the PV-ARC databases, respectively. At pandemic start, 560 patients (413 MF and 147 PV) were receiving ruxolitinib and were included in this analysis. Ruxolitinib dose was evaluable in 135 and 409 PV and MF patients, respectively. Median dose at pandemic start was 5–10 mg BID in all PV and 189 (46.2%) MF patients, 15 mg BID and 20 mg BID in 114 (27.9%) and 106 (25.9%) MF patients.

From February 2020 to January 2022, 83 (14.2%) patients acquired the Covid19 disease (PV *n* = 16, 10.8%; MF *n* = 67, 16.2%; *p* = 0.12), with an overall incidence rate of 10.5 per 100 patient-years. Overall, 15, 41, and 27 infections were observed during the first, second, and third pandemic wave, with incidence rates of 6.5,

7.8, and 7.3 per 100 patient-years in the three waves, respectively (*p* = 0.75).

Infection was asymptomatic/mild in 21 patients (25.3%), moderate in 17 (20.5%), severe in 18 (21.7%), critical in 6 (7.2%) and fatal in 21 (25.3%) patients (Supplementary Fig. 1).

Characteristics associated with Covid19 infection and hospitalization

Differences between non-Covid19 and Covid19 ruxolitinib-treated patients are summarized in Table 1. Overall, 371/467 evaluable patients (79.4%) received ≥ 1 dose of anti-SARS-CoV2 vaccine. All but one patient received an mRNA vaccine (BioNTech/Pfizer *n* = 327 [88.1%, Moderna *n* = 43 [11.6%]).

Compared to Covid19 patients, those who did not acquire the infection had more frequently received ≥ 1 dose of anti-SARS-CoV2 vaccine (*p* < 0.001). The protective effect of vaccination was




Fig. 1 Risk factors. Risk factors associated with hospitalization (**a**) and survival after Covid19 (**b**). Overall, the percentage of patients aged ≥ 70 or with $NLR \geq 5.5$ was comparable across the three Covid19 waves. Risk factors for hospitalization and mortality were calculated by Cox proportional hazard model.

confirmed also in the MF and in the PV population separately (39.5% and 56.3% of vaccinated patients vs. 82.5% and 86.8% of unvaccinated patients with Covid19 infection in MF and PV, $p < 0.001$ and $p = 0.003$, respectively).

All the 45 (54.2%) patients with severe, critical, fatal infections were hospitalized. The frequency of hospitalization in the first and second waves (66 and 68%) was higher compared to the third one (26%), ($p = 0.002$). Compared to outpatients, those admitted to hospital were more likely to be ≥ 70 years ($p = 0.05$), had a significantly lower median platelet counts (150 vs. $226 \times 10^9/L$, $p = 0.02$) and higher neutrophil counts (7.2 vs. $4.2 \times 10^9/L$, $p = 0.04$), with a significant increase of neutrophil to lymphocyte ratio (NLR) (5.6 vs. 3.5 , $p = 0.04$). At Covid19 diagnosis, ruxolitinib was reduced in 11 (13.3%) patients. Ruxolitinib discontinuation occurred in 9 patients (10.8%) in the 1st, 2nd and 3 wave in 4, 4 and 1 patients, respectively, and comparably in MF and PV. The cause of discontinuation was severe Covid19 infection in all cases,

together with severe thrombocytopenia (platelet $< 50 \times 10^9/L$) in 2 cases.

In multivariate analysis, $NLR \geq 5.5$, (HR[95%CI]: 2.47, [1.06–5.77], $p = 0.04$) and being vaccinated (HR[95%CI]: 0.16 [0.05–0.48], $p = 0.001$) remained associated with increased and reduced risk of hospitalization, respectively (Fig. 1a).

Analyzing MF patients only, hospitalized patients were older (64.5 vs 72.2 years, $p = 0.02$), had a lower median level of hemoglobin (9.9 vs 11 g/dL, $p = 0.004$) and platelet counts (130 vs. $221 \times 10^9/L$, $P = 0.002$) and higher neutrophil counts (7.3 vs. $3.8 \times 10^9/L$, $p = 0.04$), with a significant increase of NLR (5.6 vs. 3.4 , $p = 0.03$). Also, the absence of spleen response and not being vaccinated at Covid19 infection remained significantly associated with hospitalization (OR[95%CI]: 3.38[1.04–11], $p = 0.04$) and (OR[95%CI]: 6.7[1.99–22], $p = 0.002$). PV hospitalized patients presented more frequently comorbidities (57.1% versus 11.1%, $p = 0.045$)

Notably, 12 thromboses (10 venous, 2 arterial) were observed, with an incidence rate (IR) of 1.9 per 100 patient-years. Two venous thromboses occurred in Covid19 patients (all hospitalized) (IR 6.7 per 100 patient-years) and 10 thromboses occurred in non-Covid19 patients (IR 1.7 per 100 patient-years, $p = 0.05$). Out of 505 evaluable patients, 8/384 (2.1%) and 4/121 (3.3%) thromboses occurred in MF and PV patients, respectively ($p = 0.44$). Since NLR has been observed as a novel predictor of venous thrombosis in polycythemia vera [11], we investigated the risk associated with $NLR \geq 5.5$ for thrombosis in SARS-CoV-2 infected patients, but no significant association was found, possibly due to small sample size (OR[95%CI]: 0.74[0.63–8.67], $p = 0.81$).

Characteristics associated with Covid19-related mortality

Overall, 21 patients died due to Covid19 infection, after a median time of 8 days (range, 4–44) from Covid19 diagnosis. All were hospitalized. Among the 9 patients who discontinued ruxolitinib, 5 died ($p = 0.05$) (Supplementary Fig. 2). The frequency of Covid19-related deaths decreased over time, with 46.7% (7/15), 29.3% (12/41) and 7.4% (2/27) of deceased patients in the first, second and third wave, respectively ($p = 0.01$).

In multivariable analysis, probability of survival was significantly lower in patients with $NLR \geq 6.8$ (HR[95%CI]: 5.77[1.46–22.80], $p = 0.01$). Conversely, vaccination was associated with reduced risk of death (HR[95%CI]: 0.11[0.02–0.63], $p = 0.01$) (Fig. 1b).

DISCUSSION

This study provides epidemiological data on Covid19 infection in MPN patients treated with ruxolitinib, showing that 14.2% of such patients acquired the infection, with an incidence rate of 10.5×100 patients-years. The incidence did not change significantly in the three waves. This confirms previous reports on MPN patients [12] and probably reflects the rapid administration of vaccines in these oncological patients, with reduced spread of the most infectious variants. Indeed, only vaccination status could significantly reduce the risk of infection in this cohort.

However, among infected and hospitalized patients, 32.9% and 13.9% were vaccinated, respectively. These data are slightly higher than those recently described in a general population of MPNs [12], and are possibly due to a negative impact of ruxolitinib. Conversely, these incidences are superior to those reported in patients with more aggressive hematological neoplasms, in which Covid19 infection was severe in 60.7% of vaccinated patients [13]. A high NLR ratio, suggestive for a high degree of inflammation, was also associated with hospitalization and death, as already noted [14].

In MF patients, a significant association between lack of spleen response to ruxolitinib and increased risk of hospitalization was observed. This data reinforces the protective role of response on outcome [15].

Finally, we confirmed that mortality in patients with MPN and Covid19 is high, particularly in the elderly and unvaccinated and who abruptly discontinued ruxolitinib during the acute phase of infection [5, 1]. These findings were shown in the first wave of pandemic, sustained by the wild-type virus, and declined significantly during the third wave, as already reported [12].

Overall, this analysis highlights that ruxolitinib-treated patients represent a frail cohort with high Covid19-related morbidity and mortality. The absence of vaccination, particularly in patients ≥ 70 years and with high NLR, is associated with severe infection and reduced survival. In MF patients, lack of spleen response to ruxolitinib predicts hospitalization. These features should prompt anti-viral therapy in ruxolitinib-treated patients.

Francesca Palandri ^{1,3}, Elena M. Elli², Giuseppe Auteri^{1,3}, Massimiliano Bonifacio ⁴, Giulia Benevolo⁵, Florian H. Heidel⁶, Simona Paglia ¹, Malgorzata M. Trawinska⁷, Costanza Bosi⁸, Elena Rossi^{9,10}, Mario Tiribelli ¹¹, Alessia Tieghi ¹², Alessandra Iurlo ¹³, Nicola Polverelli ¹⁴, Giovanni Caocci ¹⁵, Gianni Binotto¹⁶, Francesco Cavazzini¹⁷, Eloise Beggiato⁵, Daniela Cilloni¹⁸, Caterina Tatarelli¹⁹, Francesco Mendicino²⁰, Maurizio Miglino^{21,22}, Monica Bocchia²³, Monica Crugnola²⁴, Camilla Mazzoni^{1,3}, Andrea D. Romagnoli^{1,3}, Giovanni Rindone², Sara Ceglie⁹, Alessandra D'Addio²⁵, Eleonora Santoni⁴, Daniele Cattaneo¹³, Daniela Bartoletti¹, Roberto M. Lemoli^{21,22}, Mauro Krampera ⁴, Antonio Cuneo¹⁷, Gianpietro C. Semenzato ¹⁶, Roberto Latagliata²⁶, Elisabetta Abruzzese ⁷, Nicola Vianelli¹, Michele Cavo ^{1,3}, Alessandro Andriani²⁷, Valerio De Stefano ^{9,10}, Giuseppe A. Palumbo ²⁸ and Massimo Breccia ²⁹

¹IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy. ²Hematology Division, San Gerardo Hospital, ASST Monza, Monza, Italy. ³Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy. ⁴Section of Hematology, Department of Medicine, University of Verona, Verona, Italy. ⁵Hematology U, Department of Oncology, Città della Salute e della Scienza, Turin, Italy. ⁶Innere Medicine C, Universitätsmedizin Greifswald, Greifswald, Germany. ⁷Hematology, S.Eugenio Hospital, Tor Vergata University, ASL Roma2, Rome, Italy. ⁸Division of Hematology, AUSL di Piacenza, Piacenza, Italy. ⁹Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University School of Medicine, Rome, Italy. ¹⁰Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. ¹¹Division of Hematology and BMT, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy. ¹²Department of Hematology, Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy. ¹³Hematology Division, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. ¹⁴Unit of Blood Diseases and Stem Cell Transplantation, ASST Spedali Civili di Brescia, Brescia, Italy. ¹⁵Hematology Unit, Businco Hospital, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy. ¹⁶Unit of Hematology and Clinical Immunology, University of Padova, Padova, Italy. ¹⁷Division of Hematology, University of Ferrara, Ferrara, Italy. ¹⁸Haematology Division, Department of Clinical and Biological Sciences, Ospedale San Luigi di Orbassano, University of Turin, Orbassano, Italy. ¹⁹Hematology, S.Andrea Hospital, Rome, Italy. ²⁰Unit of Hematology, Hospital of Cosenza, Cosenza, Italy. ²¹IRCCS Policlinico San Martino, Genova, Italy. ²²Dipartimento di Medicina interna e Specialità mediche, Università di Genova, Genova, Italy. ²³Hematology Unit, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy. ²⁴Division of Hematology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy. ²⁵Division of Hematology, Onco-hematologic Department, AUSL della Romagna, Ravenna, Italy. ²⁶Hematology Unit, Ospedale Belcolle, Viterbo, Italy. ²⁷Villa Betania Hospital, Roma, Italy. ²⁸Dipartimento di Scienze Mediche, Chirurgiche e Tecnologie Avanzate "G.F. Ingrassia", Università degli Studi di Catania, Catania, Italy. ²⁹A.O.U. Policlinico Umberto I, Università degli Studi di Roma "La Sapienza", Rome, Italy. ✉email: francesca.palandri@unibo.it

DATA AVAILABILITY

The datasets generated during and analyzed during the current study are available from the corresponding author on reasonable request.

REFERENCES

1. Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. *Lancet Haematol.* 2020;7:e737–45.

2. Barbui T, Vannucchi AM, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, et al. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. *Leukemia* [Internet]. 2021;35:485–93.
3. Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. *Am J Hematol* [Internet]. 2021;96:145–62.
4. Elli EM, Baratè C, Mendicino F, Palandri F, Palumbo GA. Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib. *Front Oncol* [Internet]. 2019;9:1186.
5. Barbui T, Vannucchi AM, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, et al. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. *Leukemia* [Internet]. 2021;35:485–93.
6. Auteri G, Bartoletti D, di Pietro C, Sutto E, Mazzoni C, Romagnoli AD, et al. Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity. *Leuk Res* [Internet]. 2022;116:106819.
7. Palumbo GA, Cambria D, la Spina E, Duminuco A, Laneri A, Longo A, et al. Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine. *Front Oncol* [Internet]. 2023;13:518.
8. Benevolo G, Elli EM, Bartoletti D, Latagliata R, Tiribelli M, Heidel FH, et al. Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. *Hematol Oncol* [Internet]. 2021;39:409–18.
9. Palandri F, Palumbo GA, Bonifacio M, Tiribelli M, Benevolo G, Martino B, et al. Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. *Oncotarget* [Internet]. 2017;8:79073–86.
10. Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at <https://www.covid19treatmentguidelines.nih.gov>.
11. Carobbio A, Vannucchi AM, de Stefano V, Masciulli A, Guglielmelli P, Loscocco GG, et al. Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera. *Blood Cancer J* [Internet]. 2022;12:28.
12. Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Carioli G, et al. Second versus first wave of COVID-19 in patients with MPN. *Leukemia* [Internet]. 2022;36:897–900.
13. Pagano L, Salmanton-García J, Marchesi F, López-García A, Lamure S, Itri F, et al. COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA. *Blood* [Internet]. 2022;139:1588–92.
14. Barbui T, Carobbio A, Ghirardi A, Iurlo A, Sobas MA, Elli EM, et al. Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19. *Am J Hematol* [Internet]. 2022;97:E470–3.
15. Palandri F, Palumbo GA, Bonifacio M, Breccia M, Latagliata R, Martino B, et al. Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: results from a multicentre study on 284 patients. *Leuk Res* [Internet]. 2018;74:86–8.

ACKNOWLEDGEMENTS

This work was supported by BolognAIL and by the Italian Ministry of Health.

AUTHOR CONTRIBUTIONS

FP and MB designed and supervised the study, wrote the original draft of the manuscript, and reviewed the final version. DB, SP: performed the statistical analysis and created tables and figures. All Authors collected data, reviewed the manuscript, and gave final approval to the manuscript.

FUNDING

The work reported in this publication was funded by the Italian Ministry of Health, RC-2022-2773402 e RC-2022-2773427.

COMPETING INTERESTS

F.P. consultancy and honoraria from Novartis, Celgene, AOP, Sierra Oncology and CTI; G.Be. honoraria from Novartis, Janssen, Amgen, Takeda, BMS; A.lu., M.Br. and M.Bo. honoraria from Novartis, BMS, Pfizer, Incyte; M.Cr honoraria from Novartis, Amgen; G.S. honoraria from Abbvie, Roche, Takeda; G.Bi. honoraria from Novartis, Incyte, BMS-Celgene, Pfizer; R.M.L. honoraria from Jazz, Pfizer, AbbVie, BMS, Sanofi, StemLine. F.H.H. consultancy for Novartis, CTI and Celgene and research funding from Novartis; M. Ca acted as consultant and received honoraria from Janssen, BMS Celgene, SanoFi, GlaxoSmithKline, Takeda, Amgen, Oncopeptides, AbbVie, Karyopharm, and Adaptive. E. A. honoraria from Novartis, BMS, Pfizer, and Incyte. N.V. consultancy and honoraria from Novartis, Amgen, Sobi, Grifols e Sanofi. V.D.S. consultant honoraria and speaker fees from AbbVie, Alexion, Amgen, AOP Health, Argenx, Bristol Myers Squibb, Grifols, GlaxoSmithKline, Leo Pharma, Novartis, Novo Nordisk, Sanofi, SOBI, Takeda. D. C. honoraria from Novartis, BMS, Incyte and Pfizer. M.B. honoraria from Novartis, Incyte, Astrazeneca, Janssen. G.A.P. honoraria from Abbvie, AOP, AstraZeneca, BMS Celgene, Novartis, Incyte, Janssen, Takeda; M. T. consultancy and honoraria from Novartis. M. M. T. consultancy and honoraria from Novartis. F.C. honoraria from Novartis, Incyte, and Pfizer, R.L. honoraria from Novartis, Celgene, BMS, Janssen; E.R., A.D., E.S., A.A, S.C., M.K, N.P., G.A., S.P., D.B., A.D.R., C.M., G.C, G.R., E.M.E., M.F., A.C., E.B., C.T, C.B., D.C., M.M., A.T. have no conflict of interest to disclose.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41408-023-00834-6>.

Correspondence and requests for materials should be addressed to Francesca Palandri.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023